“Expression of CD28 by bone marrow stromal cells and its involvement in B lymphopoiesis”. Journal of Immunology169 (5): 2292–2302. (September 2002). doi:10.4049/jimmunol.169.5.2292. PMID12193694.
“Loss of surface antigens is a conserved feature of apoptotic lymphocytes from several mammalian species”. Cellular Immunology271 (1): 163–172. (2011). doi:10.1016/j.cellimm.2011.06.018. PMID21745657.
“T cell antigen CD28 binds to the GRB-2/SOS complex, regulators of p21ras”. European Journal of Immunology25 (4): 1044–1050. (April 1995). doi:10.1002/eji.1830250428. PMID7737275.
“The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses”. Annual Review of Immunology20 (1): 29–53. (April 2002). doi:10.1146/annurev.immunol.20.091101.091806. PMID11861596.
“CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism”. Journal of Immunology177 (2): 1052–1061. (July 2006). doi:10.4049/jimmunol.177.2.1052. PMID16818761.
“Roquin differentiates the specialized functions of duplicated T cell costimulatory receptor genes CD28 and ICOS”. Immunity30 (2): 228–241. (February 2009). doi:10.1016/j.immuni.2008.12.015. PMID19217324.
“Human eosinophils express and release IL-13 following CD28-dependent activation”. Journal of Leukocyte Biology72 (4): 769–779. (October 2002). doi:10.1189/jlb.72.4.769. PMID12377947.
“B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes”. Immunity12 (4): 431–440. (April 2000). doi:10.1016/s1074-7613(00)80195-8. PMID10795741.
“Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4”. Immunity3 (5): 541–547. (November 1995). doi:10.1016/1074-7613(95)90125-6. PMID7584144.
“Preclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monovalent Fab' antibody”. American Journal of Transplantation12 (10): 2630–2640. (October 2012). doi:10.1111/j.1600-6143.2012.04164.x. PMID22759318.
“GRID: a novel Grb-2-related adapter protein that interacts with the activated T cell costimulatory receptor CD28”. Journal of Immunology164 (11): 5805–5814. (June 2000). doi:10.4049/jimmunol.164.11.5805. PMID10820259.
“Grb2 forms an inducible protein complex with CD28 through a Src homology 3 domain-proline interaction”. The Journal of Biological Chemistry273 (33): 21194–21202. (August 1998). doi:10.1074/jbc.273.33.21194. PMID9694876.
“Signal transduction by CD28 costimulatory receptor on T cells. B7-1 and B7-2 regulation of tyrosine kinase adaptor molecules”. The Journal of Biological Chemistry271 (3): 1591–1598. (January 1996). doi:10.1074/jbc.271.3.1591. PMID8576157.
“Two distinct intracytoplasmic regions of the T-cell adhesion molecule CD28 participate in phosphatidylinositol 3-kinase association”. The Journal of Biological Chemistry271 (16): 9403–9409. (April 1996). doi:10.1074/jbc.271.16.9403. PMID8621607.
“Expression of CD28 by bone marrow stromal cells and its involvement in B lymphopoiesis”. Journal of Immunology169 (5): 2292–2302. (September 2002). doi:10.4049/jimmunol.169.5.2292. PMID12193694.
“Loss of surface antigens is a conserved feature of apoptotic lymphocytes from several mammalian species”. Cellular Immunology271 (1): 163–172. (2011). doi:10.1016/j.cellimm.2011.06.018. PMID21745657.
“T cell antigen CD28 binds to the GRB-2/SOS complex, regulators of p21ras”. European Journal of Immunology25 (4): 1044–1050. (April 1995). doi:10.1002/eji.1830250428. PMID7737275.
“The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses”. Annual Review of Immunology20 (1): 29–53. (April 2002). doi:10.1146/annurev.immunol.20.091101.091806. PMID11861596.
“CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism”. Journal of Immunology177 (2): 1052–1061. (July 2006). doi:10.4049/jimmunol.177.2.1052. PMID16818761.
“Roquin differentiates the specialized functions of duplicated T cell costimulatory receptor genes CD28 and ICOS”. Immunity30 (2): 228–241. (February 2009). doi:10.1016/j.immuni.2008.12.015. PMID19217324.
“Human eosinophils express and release IL-13 following CD28-dependent activation”. Journal of Leukocyte Biology72 (4): 769–779. (October 2002). doi:10.1189/jlb.72.4.769. PMID12377947.
“B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes”. Immunity12 (4): 431–440. (April 2000). doi:10.1016/s1074-7613(00)80195-8. PMID10795741.
“Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4”. Immunity3 (5): 541–547. (November 1995). doi:10.1016/1074-7613(95)90125-6. PMID7584144.
“Preclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monovalent Fab' antibody”. American Journal of Transplantation12 (10): 2630–2640. (October 2012). doi:10.1111/j.1600-6143.2012.04164.x. PMID22759318.
“GRID: a novel Grb-2-related adapter protein that interacts with the activated T cell costimulatory receptor CD28”. Journal of Immunology164 (11): 5805–5814. (June 2000). doi:10.4049/jimmunol.164.11.5805. PMID10820259.
“Grb2 forms an inducible protein complex with CD28 through a Src homology 3 domain-proline interaction”. The Journal of Biological Chemistry273 (33): 21194–21202. (August 1998). doi:10.1074/jbc.273.33.21194. PMID9694876.
“Signal transduction by CD28 costimulatory receptor on T cells. B7-1 and B7-2 regulation of tyrosine kinase adaptor molecules”. The Journal of Biological Chemistry271 (3): 1591–1598. (January 1996). doi:10.1074/jbc.271.3.1591. PMID8576157.
“Two distinct intracytoplasmic regions of the T-cell adhesion molecule CD28 participate in phosphatidylinositol 3-kinase association”. The Journal of Biological Chemistry271 (16): 9403–9409. (April 1996). doi:10.1074/jbc.271.16.9403. PMID8621607.